The development programs of the company include radiotherapeutic, radioimmunotherapeutic and immunotherapeutic products for treatment of various solid cancers. The companys’s lead candiate Radspherin is currently developed for two indications, peritoneal carcinomatosis from ovarian cancer and from colorectal cancer, but are also relevant for treating other types of cancers.
The company has developed proprietary antibodies and holds a license for other antibodies. The antibodies are used as targeting modules of the immune-and radioimmunotherapeutic candidates and are currently in a discovery phase. Oncoinvent has a strategy to be a multiple compound company and will continue to focus on developing new product candidates.